25 April 2014
 

Patient self-report outcomes to guide a treat-to-target strategy in clinical trials and usual clinical care of rheumatoid arthritis

Rheumatology ArticleI. Castrejón, T. Pincus

New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY, USA. isabelcastrejonf@gmail.com

CER6026 Submission on line
B. Clinical trials

Free to view (click on article PDF icon to read the article)

Abstract

Patient self-report questionnaires provide an easily-implemented approach for quantitative assessment of patients with rheumatoid arthritis (RA) in usual care settings. Patient reported outcomes (PROs) on these questionnaires and an index including only patient self-report measures, RAPID3 (Routine Assessment of Patient Index Data), distinguish active from control treatments as effectively as other measures in clinical trials of methotrexate, leflunomide, adalimumab, abatacept, and certolizumab. RAPID3 is correlated significantly with indices that include formal joint counts and laboratory tests, such as disease activity score 28 (DAS28) and clinical disease activity index (CDAI), in clinical trials and clinical care, including categories for high, moderate, low severity, and remission. Patient self-report questionnaires present additional advantages that the same observer (the patient) completes quantitative scores at each encounter regardless of the setting and the patient does most of the work to provide an index. Completion of a questionnaire helps the patient prepare for the visit, and improves doctor-patient communication. This article summarises evidence concerning PROs in clinical trials and clinical care in documenting low disease activity and remission, including a meta-analysis of studies that document the value of using PROs to implement `treat-to-target.` Patient self-report questionnaires must be complemented by a careful joint examination, and do not prevent performance of a formal joint count or any other measure by a treating physician. Patient self-report questionnaires may provide a useful, cost-effective method to implement treat-to-target in patients with RA as well as other rheumatic diseases.

PMID: 23079199 [PubMed]

Received: 25/09/2012 - Accepted : 25/09/2012 - In Press: 16/10/2012 - Published: 20/11/2012

Top of the Page

Web sites for on line Journals
© Clinical and Experimental Rheumatology (Journal with On line Submission) ISSN n° 1593-098X
- VAT IT-00783170509